The infantile myofibromatosis NOTCH3 L1519P mutation leads to hyperactivated ligand-independent Notch signaling and increased PDGFRB expression
Authors:
- Dan WuDWDan Wu
- Sailan WangSWSailan Wang
- Daniel V. OliveiraDODaniel V. Oliveira
- Francesca Del GaudioFGFrancesca Del Gaudio
- Michael VanlandewijckMVMichael Vanlandewijck
- Thibaud LebouvierTLThibaud Lebouvier
- Christer BetsholtzCBChrister Betsholtz
- Jian ZhaoJZJian Zhao
- ShaoBo JinSJShaoBo Jin
- Urban LendahlULUrban Lendahl
- Helena KarlströmHKHelena Karlström
Open Access
- 1 February 2021
- journal article
- research article
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 14 (2)
Abstract
Infantile myofibromatosis (IMF) is a benign tumor form characterized by the development of nonmetastatic tumors in skin, bone, muscle and sometimes viscera. Autosomal-dominant forms of IMF are caused by mutations in the PDGFRB gene, but a family carrying a L1519P mutation in the NOTCH3 gene has also recently been identified. In this study, we address the molecular consequences of the NOTCH3L1519P mutation and the relationship between Notch and PDGFRB signaling in IMF. The NOTCH3L1519P receptor generates enhanced downstream signaling in a ligand-independent manner. Despite the enhanced signaling, the NOTCH3L1519P receptor is absent from the cell surface and instead accumulates in the endoplasmic reticulum. Furthermore, the localization of the NOTCH3L1519P receptor in the bipartite, heterodimeric state is altered, combined with avid secretion of the mutated extracellular domain from the cell. Chloroquine treatment strongly reduces the amount of secreted NOTCH3L1519P extracellular domain and decreases signaling. Finally, NOTCH3L1519P upregulates PDGFRB expression in fibroblasts, supporting a functional link between Notch and PDGF dysregulation in IMF. Collectively, our data define a NOTCH3–PDGFRB axis in IMF, in which an IMF-mutated NOTCH3 receptor elevates PDGFRB expression. The functional characterization of a ligand-independent gain-of-function NOTCH3 mutation is important for Notch therapy considerations for IMF, including strategies aimed at altering lysosome function.Keywords
Funding Information
- Cancerfonden
- Swedish Research Council
- Demensfonden
- Karolinska Institutet
This publication has 36 references indexed in Scilit:
- Blockade of individual Notch ligands and receptors controls graft-versus-host diseaseJournal of Clinical Investigation, 2013
- Targeting the PDGF signaling pathway in tumor treatmentCell Communication and Signaling, 2013
- Risk‐adapted therapy for infantile myofibromatosis in childrenPediatric Blood & Cancer, 2011
- Quantifying colocalization by correlation: The Pearson correlation coefficient is superior to the Mander's overlap coefficientCytometry Part A, 2010
- Role of platelet-derived growth factors in physiology and medicineGenes & Development, 2008
- Activating NOTCH3 mutation in a patient with small-vessel-disease of the BrainHuman Mutation, 2008
- Platelet‐derived growth factor receptors and ligands are up‐regulated in paediatric fibromatosesHistopathology, 2007
- High levels of Notch signaling down-regulate Numb and NumblikeJournal of Cell Biology, 2006
- PDGF signaling in cells and miceCytokine & Growth Factor Reviews, 2004
- The Low pH in Trans-Golgi Triggers Autocatalytic Cleavage of Pre-α-inhibitor Heavy Chain PrecursorJournal of Biological Chemistry, 2000